atevirdine

Atevirdine is a synthetic small molecule classified as a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was primarily studied for the treatment of human immunodeficiency virus (HIV) infection. It acts by binding noncompetitively near the catalytic site of HIV-1 reverse transcriptase, thereby inhibiting viral replication by blocking the transcription of viral RNA into DNA. Atevirdine demonstrated activity against AZT-resistant strains of HIV and was considered a first-generation member of the bisheteroarylpiperazine class of NNRTIs. Clinical trials reached phase I/II, but clinical data were insufficient to determine its definitive role in HIV therapy, and it has not been approved for marketing[1][2][3][5][6][7].

Other names

atevirdine mesylate